Published on 23 Jun 2023 on Zacks via Yahoo Finance
Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal
Horizon Therapeutics HZNP announced positive top-line results from its ongoing phase III study on Tepezza for the treatment of Thyroid Eye Disease (TED) in Japanese patients with higher levels of disease activity. The metric used for disease activity is clinical activity score (CAS).
The primary efficacy endpoint of the late-stage study is the proptosis (eye bulging) response rate at week 24. This primary endpoint was measured by observing the percentage of participants achieving at least a 2 mm reduction in proptosis from baseline in the study eye, without any adverse side effect in the fellow eye.
Year to date, shares of Horizon have declined 10.9% compared with the industry’s 7.6% fall.